【文献解读】肝细胞癌和肝结直肠癌转移对药物洗脱珠区域肝脏治疗的反应率
2017/7/20 创新医学网

     文章来源："欧尔意OAE"微信公众号

     作者：Sofina

    

     原文出处

     Stambo GS, Cragan D. Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy. Hepatoma Res 2017;3:141-8.

     摘要

     目的：本研究的目的是评估和比较肝细胞癌(HCC)和肝结直肠癌转移对使用多柔比星和伊立替康的LC珠化疗栓塞的反应。方法：基于肿瘤学实践，作者在一个单一社区报告了他们在多柔比星和伊立替康洗脱珠中治疗13例原发性肝癌和超过1年的结直肠癌转移的25例患者的经验。在结直肠癌组中，他们比较了伊立替康洗脱珠和多柔比星洗脱珠。结果：11例多柔比星治疗的肝癌患者中有9例具有完全反应或部分反应(比例为81.8%)。所有肝癌病变体积减小，肿瘤增强，治疗后24个月内10/11(91%)肝癌患者存活。费雪精确检测显示，在22位有随访资料的结直肠癌转移患者中，与伊立替康治疗组相比，11例接受多柔比星治疗的患者明显更有可能表现出完全或部分反应。结论：总体而言，肝癌患者和结肠癌患者清晰地显示了洗脱珠的有效性，因为91%的肝癌患者在治疗后24个月存活。

     关键词：血管造影，动脉化疗栓塞，药物洗脱珠，肝细胞癌，多柔比星，伊立替康。

     Aim: The purpose of this study was to evaluate and compare how hepatocellular carcinoma (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin and irinotecan.Methods: The authors report their experience with doxorubicin and irinotecan eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases over a 1-year period at a single community based oncology practice. Within the colorectal cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results: Nine of the 11 (81.8%) doxorubicin treated HCC patients had either complete response or partial response. All of the HCC lesions showed reduction in size and tumor enhancement and 10/11 (91%) HCC patients were alive at 24 months post treatment. Fisher’s exact test revealed that among the 22 with colorectal metastases for whom follow-up data were available, those 11 who were treated with doxorubicin were significantly more likely to demonstrate complete or partial response compared to the 11 in the irinotecan treated group (P < 0.001). Conclusion: Overall, HCC and colon metastasis patients clearly demonstrated the effectiveness of drug eluting beads with 91% of the HCC patients alive 24 months after treatment.

     Keywords:Angiography, transarterial chemoembolization, drug eluting beads, hepatocellular carcinoma, doxorubicin, irinotecan.

     原文链接

     各位读者可复制此链接在浏览器中打开。

     http://hrjournal.net/article/view/1996

     或点击屏幕左下方“阅读原文”，免费获取全文!

     联系我们

     Hepatoma Research旨在报道肝癌最新研究进展，为该领域的研究学者和临床医生提供一个国际性学术交流平台。自2015年4月创刊以来，期刊读者遍布全球156个国家和地区，已在线发表文章102篇。诚挚欢迎您向我刊投稿，如有疑问，请邮件：

     editor001@hrjournal.net。

     *本文中文摘要翻译内容由 OAE Publishing Inc.北京办公室负责翻译。中文内容仅供参考，一切内容以英文原版为准。

     本文转载已获 “欧尔意OAE”微信号授权

     点击下方“阅读原文”↓↓↓

    http://weixin.100md.com
返回 创新医学网 返回首页 返回百拇医药